Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00

Posted by Francis Steltz on Aug 12th, 2026

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) had its price target increased by Needham & Company LLC from $50.00 to $66.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 52.50% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on DFTX. Stifel Nicolaus boosted their price target on Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Wells Fargo & Company began coverage on shares of Definium Therapeutics in a research note on Monday, July 27th. They set an “overweight” rating and a $68.00 target price for the company. Robert W. Baird boosted their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $57.00.

Check Out Our Latest Stock Report on DFTX

Definium Therapeutics Stock Up 5.8%

Definium Therapeutics stock traded up $2.37 during midday trading on Wednesday, hitting $43.28. The stock had a trading volume of 6,335,414 shares, compared to its average volume of 2,290,860. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock has a market cap of $4.31 billion, a P/E ratio of -12.62 and a beta of 2.23. Definium Therapeutics has a 12 month low of $8.70 and a 12 month high of $49.70. The business has a fifty day moving average price of $38.68 and a 200 day moving average price of $26.34.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Research analysts predict that Definium Therapeutics will post -2.65 EPS for the current year.

Insider Activity

In related news, CEO Robert Barrow sold 29,208 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the sale, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,096 shares of company stock worth $2,165,763 in the last 90 days. 2.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Definium Therapeutics

Hedge funds have recently made changes to their positions in the business. Cerity Partners LLC boosted its stake in Definium Therapeutics by 2.4% during the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after buying an additional 1,165 shares in the last quarter. Creative Planning raised its position in Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after acquiring an additional 1,655 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares during the last quarter. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

Positive Sentiment: Definium reported positive topline results from the Phase 3 Voyage study, saying its LSD-derived oral therapy reduced anxiety symptoms in patients with generalized anxiety disorder. This is the second positive Phase 3 trial for DT120 ODT and supports the company’s plans for potential regulatory submission. Definium says LSD-based pill reduces anxiety in late-stage study
Positive Sentiment: The favorable trial update triggered a sharp increase in trading activity and helped push DFTX closer to its 52-week high. The results may improve investor expectations for DT120’s commercial potential and future revenue growth. This LSD-Based Drug Just Scored Again. Definium Stock Soars.
Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, highlighting the market significance of the update. Separately, reported short-interest data showed no shares sold short, but the figures appeared inconsistent and may have limited analytical value.
Negative Sentiment: HC Wainwright reduced its earnings estimates across 2026–2030, including lowering its 2026 forecast to a loss of $3.05 per share from $2.10 and its 2027 forecast to a loss of $1.71 from $1.22. The revisions indicate continued heavy development spending and delay the expected earnings ramp despite the stronger clinical outlook.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.